Analysts See $-0.10 EPS for Midatech Pharma Plc (MTP)

March 19, 2018 - By Kurt Siggers

 Analysts See $ 0.10 EPS for Midatech Pharma Plc (MTP)

Analysts expect Midatech Pharma Plc (NASDAQ:MTP) to report $-0.10 EPS on April, 2. The stock decreased 2.91% or $0.03 during the last trading session, reaching $1. About 7,569 shares traded. Midatech Pharma Plc (NASDAQ:MTP) has 0.00% since March 19, 2017 and is . It has underperformed by 16.70% the S&P500.

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. The company has market cap of $25.98 million. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. It currently has negative earnings. The firm also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.